Targacept has initiated a Phase II clinical proof of concept trial of its TC-5619 drug compound for cognitive dysfunction in schizophrenia.

The study will be carried out in the US and India across 200 subjects who are already taking an approved medication from the drug calls known as atypical anti-psychotics.

The trial is expected to finish by the end of 2010. Following its completion, AstraZeneca has the right to license TC-5619 under prearranged terms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData